Intradermal Influenza Vaccine in the Young
Summary
Influenza poses a heavy burden to our health service. The WHO estimates that seasonal influenza causes 250,000-500,000 deaths worldwide each year. Various strategies including intradermal vaccination and new vaccine adjuvants have been shown to improve immunogenicity. Recently, imiquimod, a synthetic Toll-like receptor 7 (TLR7) agonist useful for the treatment of DNA virus infection, have been shown to improve vaccine immunogenicity against influenza virus in mouse model. The objective of this prospective double-blind randomized controlled trial is to evaluate the effect and safety of topical treatment with imiquimod immediately before intradermal influenza vaccination in healthy young adults.
Timeline
- Start
- 2014-03
- Primary completion
- 2014-11
- Completion
- 2014-11
Outcome
Met primary endpoint
paper seroconversion at day 7 occurred in 39 participants (98%) in the INF-Q-ID group, 25 (63%) in the INF-C-ID group PMID 26559482 ↗
paper p<0·0001 for all three vaccine strains PMID 26559482 ↗
paper the seroconversion rate against the four non-vaccine strains was better in the INF-Q-ID group than in the control groups on days 7 and 21 (p<0·0001). PMID 26559482 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imiquimod | Other / unclassified | 5 % | Topical |
| Subject | Imiquimod | Other / unclassified | 250 mg | Topical |
| Subject | Intradermal influenza vaccine | Vaccine | — | Intramuscular |
| Comparator | Intramuscular influenza vaccine | Vaccine | — | Intramuscular |